When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MRTX - Mirati' sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Mirati Therapeutics Inc.
Mirati Therapeutics (NASDAQ:MRTX) has announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO) in patients with advanced or metastatic urothelial carcinoma. Data were presented at the European Society for Medical Oncology Virtual Congress.
More news on: Mirati Therapeutics, Inc., Healthcare stocks news,